GCG and obesity due to melanocortin 4 receptor deficiency: The therapeutic performance of these drugs is somewhat disappointing, with 3–5% weight loss in patients treated with orlistat and 5–10% in those receiving naltrexone, liraglutide or phentermine.36–40 Liraglutide, which is a GLP-1 RA that was initially developed for the treatment of T2D under the trade name Victoza® (Novo Nordisk A/S, Bagsværd, Denmark; approved for use in T2D in 2009 by the EMA and in 2010 by the FDA), was approved in 2014 for the treatment of obesity up to a maximum dose of 3 mg (Saxenda) in people with a BMI of ≥30 kg/m2 or ≥27 kg/m2 and obesity-related comorbidities.